Pharmacodynamics Recent Advances of a Lipoprotein-associated Phospholipase A2 Specific Inhibitor Darapladib
文献类型：期刊论文
| 作者 | Ma Quanxin1; Chen Minli1; Wang Yiping2
|
| 刊名 | Chinese Pharmaceutical Journal
 |
| 出版日期 | 2015 |
| 卷号 | 50期号:4页码:317-322 |
| 关键词 | Darapladib atherosclerosis Lp-PLA2 Darapladib |
| ISSN号 | 1001-2494 |
| 其他题名 | 脂蛋白相关磷脂酶A2抑制剂Darapladib的药效学研究进展 |
| 文献子类 | Review |
| 英文摘要 | Lipoprotein- associated phospholipase A2 (Lp- PLA2) is a member of phospholipases superfamily which can hydrolyze oxidative phospholipid in low density lipoprotein (LDL), and produce two proinflammatory mediators including lysophosphatidylcholine (lysoPC) and oxidized free fatty acid. Thus, Lp- PLA2 is believed to mediate the inflammatory processes that lead to atherogenesis. Recent studies indicated that Lp- PLA2 acts as a new marker in the inflammatory process and is an independent predictor of the cardiovascular diseases. Many Lp- PLA2- targeted inhibitors have been designed to deal with the key enzyme involving in atherosclerosis. Darapladib is the specific inhibitor which is closest to the market among the rest and is drawn wide attention as an emerging therapy for atherosclerosis,and the clinical phase Ⅲ trials have been completed. Numerous experiments have confirmed that Darapladib could decrease the activity of Lp- PLA2,reduce inflammatory reaction and disrupt the development of atherosclerosis. In this paper, the authors summarized the mechanism of Lp- PLA2 and Darapladib in atherosclerosis, and the recent advances on the pharmacodynamics of Darapladib in recent years. |
| 资助项目 | 国家科技重大专项子课题[00000000] ; 浙江省卫生高层次创新人才培养工程项目资助[00000000] |
| WOS研究方向 | General & Internal Medicine (provided by Clarivate Analytics) |
| 语种 | 中文 |
| CSCD记录号 | CSCD:5354597 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/269295]  |
| 专题 | 药理学第一研究室 |
| 作者单位 | 1.Laboratory Animal Research Center, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.; 2.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. |
| 推荐引用方式 GB/T 7714 | Ma Quanxin,Chen Minli,Wang Yiping. Pharmacodynamics Recent Advances of a Lipoprotein-associated Phospholipase A2 Specific Inhibitor Darapladib[J]. Chinese Pharmaceutical Journal,2015,50(4):317-322. |
| APA | Ma Quanxin,Chen Minli,&Wang Yiping.(2015).Pharmacodynamics Recent Advances of a Lipoprotein-associated Phospholipase A2 Specific Inhibitor Darapladib.Chinese Pharmaceutical Journal,50(4),317-322. |
| MLA | Ma Quanxin,et al."Pharmacodynamics Recent Advances of a Lipoprotein-associated Phospholipase A2 Specific Inhibitor Darapladib".Chinese Pharmaceutical Journal 50.4(2015):317-322. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。